As an example, the activation of IFNG, an activatory target of chronic granulomatous disease, was predicted to lead to therapeutic effects on rheumatoid arthritis (RA), Parkinson’s disease (PD), type I diabetes mellitus (T1DM), acute myeloid leukemia (AML) and breast cancer (BC). This evidence concerns the gene IFNG and acute myeloid leukemia.